在线客服: 点击这里给我发消息  新用户使用步骤:会员注册→充值→重新登入→进入资源
标题:Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
时间:2020-01-15 09:59:18
DOI:10.1016/j.it.2016.04.010
PMID:27216414
作者:Hughes, Paul E.; Caenepeel, Sean; Wu, Lawren C.
出版源: 《Trends in Immunology》 :S1471490616300333
摘要:Targeted therapies inhibit tumor-intrinsic drivers of growth and can elicit significant but transient clinical responses. Immunotherapies enhance host antitumor immunity and can elicit durable responses in subsets of patients across multiple tumor types. Checkpoint inhibitors are immunotherapies that relieve suppressive signals acting on host T cells to unleash antitumor T cell activity. In some cases, targeted therapies can enhance aspects of cancer immunity, such as tumor antigenicity, T cell trafficking, or T cell infiltration into tumors, which provides a rationale for combining them with checkpoint inhibitors or other cancer immunotherapies that may lead to synergistic efficacy. Considerations for the clinical development of combinations of targeted therapies and immunotherapies include optimizing dosing regimens, minimizing treatment related toxicities, and selecting appropriate biomarkers and endpoints to assess efficacy.
大小:2256 kb
页数:16 PAGES
下载: 点击下载
预览:

浏览器不支持嵌入PDF阅读,打开新页面在线阅读

目录:
  • Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
    • Introduction
    • T Cell Checkpoint Therapies
    • Combinations of MAPK Pathway Inhibitors with Checkpoint Therapies
    • Combinations of VEGF Pathway Inhibitors with Checkpoint Therapies
    • Considerations for the Clinical Development of Targeted and Checkpoint Therapy Combinations
    • Concluding Remarks
    • Disclaimer Statement
    • Acknowledgments
    • References

本页内容由网络收集而来,版权归原创者所有,如有侵权请及时联系